Prediagnostic blood selenium status and mortality among patients with colorectal cancer in western european populations

Jacqueline Roshelli Baker; Sushma Umesh; Mazda Jenab; Lutz Schomburg; Anne Tjønneland; Anja Olsen; Marie Christine Boutron-Ruault; Joseph A. Rothwell; Gianluca Severi; Verena Katzke; Theron Johnson; Matthias B. Schulze; Giovanna Masala; Claudia Agnoli; Vittorio Simeon; Rosario Tumino; H. Bas Bueno-De-mesquita; Inger Torhild Gram; Guri Skeie; Catalina Bonet; Miguel Rodriguez-Barranco; José María Houerta; Björn Gylling; Bethany Van Guelpen; Aurora Perez-Cornago; Elom Aglago; Heinz Freisling; Elisabete Weiderpass; Amanda J. Cross; Alicia K. Heath; David J. Hughes; Veronika Fedirko

doi:10.3390/biomedicines9111521

Prediagnostic blood selenium status and mortality among patients with colorectal cancer in western european populations

Jacqueline Roshelli Baker, Sushma Umesh, Mazda Jenab, Lutz Schomburg, Anne Tjønneland, Anja Olsen, Marie Christine Boutron-Ruault, Joseph A. Rothwell, Gianluca Severi, Verena Katzke, Theron Johnson, Matthias B. Schulze, Giovanna Masala, Claudia Agnoli, Vittorio Simeon, Rosario Tumino, H. Bas Bueno-De-mesquita, Inger Torhild Gram, Guri Skeie, Catalina BonetMiguel Rodriguez-Barranco, José María Houerta, Björn Gylling, Bethany Van Guelpen, Aurora Perez-Cornago, Elom Aglago, Heinz Freisling, Elisabete Weiderpass, Amanda J. Cross, Alicia K. Heath, David J. Hughes^*, Veronika Fedirko

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

19 Citationer (Scopus)

8 Downloads (Pure)

Abstract

A higher selenium (Se) status has been shown to be associated with lower risk for colorectal cancer (CRC), but the importance of Se in survival after CRC diagnosis is not well studied. The associations of prediagnostic circulating Se status (as indicated by serum Se and selenoprotein P (SELENOP) measurements) with overall and CRC-specific mortality were estimated using multi-variable Cox proportional hazards regression among 995 CRC cases (515 deaths, 396 from CRC) in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Se and SELENOP serum concentrations were measured on average 46 months before CRC diagnosis. Median follow-up time was 113 months. Participants with Se concentrations in the highest quintile (≥100 µg/L) had a multivariable-adjusted hazard ratio (HR) of 0.73 (95% CI: 0.52–1.02; P_trend = 0.06) for CRC-specific mortality and 0.77 (95% CI: 0.57–1.03; P_trend = 0.04) for overall mortality, compared with the lowest quintile (≤67.5 µg/L). Similarly, participants with SELENOP concentrations in the highest (≥5.07 mg/L) compared with the lowest quintile (≤3.53 mg/L) had HRs of 0.89 (95% CI: 0.64–1.24; P_trend = 0.39) for CRC-specific mortality and 0.83 (95% CI: 0.62–1.11; P_trend = 0.17) for overall mortal-ity. Higher prediagnostic exposure to Se within an optimal concentration (100–150 µg/L) might be associated with improved survival among CRC patients, although our results were not statistically significant and additional studies are needed to confirm this potential association. Our findings may stimulate further research on selenium’s role in survival among CRC patients especially among those residing in geographic regions with suboptimal Se availability.

Originalsprog	Engelsk
Artikelnummer	1521
Tidsskrift	Biomedicines
Vol/bind	9
Udgave nummer	11
ISSN	2227-9059
DOI	https://doi.org/10.3390/biomedicines9111521
Status	Udgivet - 2021
Udgivet eksternt	Ja

Bibliografisk note

Funding Information:
This work was supported by: The Health Research Board of Ireland project grant (HRA-POR/2013/397) to D.J.H. Support for this study was also provided by the COST Action CA17118 supported by COST (European Cooperation in Science and Technology, www.cost.eu) to D.J.H. and M.J. Moreover, V.F. is supported by the Cancer Prevention and Research Institute of Texas (CPRIT) Rising Stars Award (Grant ID RR200056). The EPIC study was supported by ?Europe Against Cancer? Program of the European Commission (SANCO); Ligue contre le Cancer; Institut Gustave Roussy; Mutuelle G?n?rale de l?Education Nationale; Institut National de la Sant? et de la Recherche M?dicale (INSERM); German Cancer Aid; German Cancer Research Center; German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health; the CIBER en Epidemiolog?a y Salud P?blica (CIBERESP), Spain; ISCIII RETIC (RD06/0020); Spanish Regional Governments of Andalusia, Asturias, Basque Country, Murcia (No. 6236) and Navarra and the Catalan Institute of Oncology; Cancer Research UK; Medical Research Council, UK; The Hellenic Health Foundation; Italian Association for Research on Cancer; Italian National Research Council; Compagnia di San Paolo; Dutch Ministry of Public Health, Welfare, and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Swedish Cancer Society; Swedish Scientific Council; Regional Governments of Skane and Vasterbotten, Sweden; and NordForsk Center of Excellence program HELGA. Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 for EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK). D.J.H. was supported by the Health Research Board of Ireland health research award HRA-PHS-2015-1142. L.S. was supported by the DFG Research Unit 2558 TraceAge, Scho 849/6-1. We would like to thank the following EPIC subcohorts for their data and contributions: (1) Direcci?n General de Salud P?blica, Consejer?a de Sanidad del Principado de Asturias, Oviedo, Spain; (2) Subdirecci?n de Salud P?blica de Gipuzkoa, Instituto de Investigaci?n BIODONOSTIA, Gobierno Vasco, CIBER de Epidemiolog?a y Salud P?blicam, San Sebastian, Spain; (3) AOU Citt? della Salute e della, Scienza di Torino and CPO-Piemonte, Turin, Italy; (4) Julius Center for Health Sciences and Primary Care of the University Medical Center Utrecht (UMCU), Utrecht, The Netherlands, Prospect-EPIC; (5) Direcci?n General de Salud P?blica, Consejer?a de Sanidad del Principado de Asturias, Oviedo, Spain; (6) Instituto de Salud P?blica, Gobierno de Navarra, Pamplona, Spain; (7) MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge: The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK (C864/A14136). Acknowledgments: We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research.

Funding Information:
Funding: This work was supported by: The Health Research Board of Ireland project grant (HRA-POR/2013/397) to D.J.H. Support for this study was also provided by the COST Action CA17118 supported by COST (European Cooperation in Science and Technology, www.cost.eu) to D.J.H. and M.J. Moreover, V.F. is supported by the Cancer Prevention and Research Institute of Texas (CPRIT) Rising Stars Award (Grant ID RR200056). The EPIC study was supported by “Europe Against Cancer” Program of the European Commission (SANCO); Ligue contre le Cancer; Institut Gustave Roussy; Mutuelle Générale de l’Education Nationale; Institut National de la Santé et de la Recherche Médicale (INSERM); German Cancer Aid; German Cancer Research Center; German Federal Ministry of Education and Research; Danish Cancer Society; Health Research Fund (FIS) of the Spanish Ministry of Health; the CIBER en Epidemiología y Salud Pública (CIBERESP), Spain; ISCIII RETIC (RD06/0020); Spanish Regional Governments of Andalusia, Asturias, Basque Country, Murcia (No. 6236) and Navarra and the Catalan Institute of Oncology; Cancer Research UK; Medical Research Council, UK; The Hellenic Health Foundation; Italian Association for Research on Cancer; Italian National Research Council; Compagnia di San Paolo; Dutch Ministry of Public Health, Welfare, and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Swedish Cancer Society; Swedish Scientific Council; Regional Governments of Skane and Vasterbotten, Sweden; and NordForsk Center of Excellence program HELGA. Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 for EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK). D.J.H. was supported by the Health Research Board of Ireland health research award HRA-PHS-2015-1142. L.S. was supported by the DFG Research Unit 2558 TraceAge, Scho 849/6-1. We would like to thank the following EPIC subcohorts for their data and contributions: (1) Dirección General de Salud Pública, Consejería de Sanidad del Principado de Asturias, Oviedo, Spain; (2) Subdirección de Salud Pública de Gipuzkoa, Instituto de Investigación BIODONOSTIA, Gobierno Vasco, CIBER de Epidemiología y Salud Públicam, San Sebastian, Spain; (3) AOU Città della Salute e della, Scienza di Torino and CPO-Piemonte, Turin, Italy; (4) Julius Center for Health Sciences and Primary Care of the University Medical Center Utrecht (UMCU), Utrecht, The Netherlands, Prospect-EPIC; (5) Dirección General de Salud Pública, Consejería de Sanidad del Principado de Asturias, Oviedo, Spain; (6) Instituto de Salud Pública, Gobierno de Navarra, Pamplona, Spain; (7) MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge: The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK (C864/A14136).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Adgang til dokumentet

10.3390/biomedicines9111521Licens: CC BY

Prediagnostic blood selenium status and mortality among patients with colorectal cancer in western european populationsForlagets udgivne version, 325 KBLicens: CC BY

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Baker, J. R., Umesh, S., Jenab, M., Schomburg, L., Tjønneland, A., Olsen, A., Boutron-Ruault, M. C., Rothwell, J. A., Severi, G., Katzke, V., Johnson, T., Schulze, M. B., Masala, G., Agnoli, C., Simeon, V., Tumino, R., Bueno-De-mesquita, H. B., Gram, I. T., Skeie, G., ... Fedirko, V. (2021). Prediagnostic blood selenium status and mortality among patients with colorectal cancer in western european populations. Biomedicines, 9(11), Artikel 1521. https://doi.org/10.3390/biomedicines9111521

Baker, JR, Umesh, S, Jenab, M, Schomburg, L, Tjønneland, A, Olsen, A, Boutron-Ruault, MC, Rothwell, JA, Severi, G, Katzke, V, Johnson, T, Schulze, MB, Masala, G, Agnoli, C, Simeon, V, Tumino, R, Bueno-De-mesquita, HB, Gram, IT, Skeie, G, Bonet, C, Rodriguez-Barranco, M, Houerta, JM, Gylling, B, Van Guelpen, B, Perez-Cornago, A, Aglago, E, Freisling, H, Weiderpass, E, Cross, AJ, Heath, AK, Hughes, DJ & Fedirko, V 2021, 'Prediagnostic blood selenium status and mortality among patients with colorectal cancer in western european populations', Biomedicines, bind 9, nr. 11, 1521. https://doi.org/10.3390/biomedicines9111521

@article{ed2e9ad3cd554fce9f9e48d38d831194,

title = "Prediagnostic blood selenium status and mortality among patients with colorectal cancer in western european populations",

abstract = "A higher selenium (Se) status has been shown to be associated with lower risk for colorectal cancer (CRC), but the importance of Se in survival after CRC diagnosis is not well studied. The associations of prediagnostic circulating Se status (as indicated by serum Se and selenoprotein P (SELENOP) measurements) with overall and CRC-specific mortality were estimated using multi-variable Cox proportional hazards regression among 995 CRC cases (515 deaths, 396 from CRC) in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Se and SELENOP serum concentrations were measured on average 46 months before CRC diagnosis. Median follow-up time was 113 months. Participants with Se concentrations in the highest quintile (≥100 µg/L) had a multivariable-adjusted hazard ratio (HR) of 0.73 (95% CI: 0.52–1.02; Ptrend = 0.06) for CRC-specific mortality and 0.77 (95% CI: 0.57–1.03; Ptrend = 0.04) for overall mortality, compared with the lowest quintile (≤67.5 µg/L). Similarly, participants with SELENOP concentrations in the highest (≥5.07 mg/L) compared with the lowest quintile (≤3.53 mg/L) had HRs of 0.89 (95% CI: 0.64–1.24; Ptrend = 0.39) for CRC-specific mortality and 0.83 (95% CI: 0.62–1.11; Ptrend = 0.17) for overall mortal-ity. Higher prediagnostic exposure to Se within an optimal concentration (100–150 µg/L) might be associated with improved survival among CRC patients, although our results were not statistically significant and additional studies are needed to confirm this potential association. Our findings may stimulate further research on selenium{\textquoteright}s role in survival among CRC patients especially among those residing in geographic regions with suboptimal Se availability.",

keywords = "Cohort, Colorectal cancer, Selenium, Selenoprotein P, Survival",

author = "Baker, {Jacqueline Roshelli} and Sushma Umesh and Mazda Jenab and Lutz Schomburg and Anne Tj{\o}nneland and Anja Olsen and Boutron-Ruault, {Marie Christine} and Rothwell, {Joseph A.} and Gianluca Severi and Verena Katzke and Theron Johnson and Schulze, {Matthias B.} and Giovanna Masala and Claudia Agnoli and Vittorio Simeon and Rosario Tumino and Bueno-De-mesquita, {H. Bas} and Gram, {Inger Torhild} and Guri Skeie and Catalina Bonet and Miguel Rodriguez-Barranco and Houerta, {Jos{\'e} Mar{\'i}a} and Bj{\"o}rn Gylling and {Van Guelpen}, Bethany and Aurora Perez-Cornago and Elom Aglago and Heinz Freisling and Elisabete Weiderpass and Cross, {Amanda J.} and Heath, {Alicia K.} and Hughes, {David J.} and Veronika Fedirko",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

doi = "10.3390/biomedicines9111521",

language = "English",

volume = "9",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "11",

}

TY - JOUR

T1 - Prediagnostic blood selenium status and mortality among patients with colorectal cancer in western european populations

AU - Baker, Jacqueline Roshelli

AU - Umesh, Sushma

AU - Jenab, Mazda

AU - Schomburg, Lutz

AU - Tjønneland, Anne

AU - Olsen, Anja

AU - Boutron-Ruault, Marie Christine

AU - Rothwell, Joseph A.

AU - Severi, Gianluca

AU - Katzke, Verena

AU - Johnson, Theron

AU - Schulze, Matthias B.

AU - Masala, Giovanna

AU - Agnoli, Claudia

AU - Simeon, Vittorio

AU - Tumino, Rosario

AU - Bueno-De-mesquita, H. Bas

AU - Gram, Inger Torhild

AU - Skeie, Guri

AU - Bonet, Catalina

AU - Rodriguez-Barranco, Miguel

AU - Houerta, José María

AU - Gylling, Björn

AU - Van Guelpen, Bethany

AU - Perez-Cornago, Aurora

AU - Aglago, Elom

AU - Freisling, Heinz

AU - Weiderpass, Elisabete

AU - Cross, Amanda J.

AU - Heath, Alicia K.

AU - Hughes, David J.

AU - Fedirko, Veronika

PY - 2021

Y1 - 2021

N2 - A higher selenium (Se) status has been shown to be associated with lower risk for colorectal cancer (CRC), but the importance of Se in survival after CRC diagnosis is not well studied. The associations of prediagnostic circulating Se status (as indicated by serum Se and selenoprotein P (SELENOP) measurements) with overall and CRC-specific mortality were estimated using multi-variable Cox proportional hazards regression among 995 CRC cases (515 deaths, 396 from CRC) in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Se and SELENOP serum concentrations were measured on average 46 months before CRC diagnosis. Median follow-up time was 113 months. Participants with Se concentrations in the highest quintile (≥100 µg/L) had a multivariable-adjusted hazard ratio (HR) of 0.73 (95% CI: 0.52–1.02; Ptrend = 0.06) for CRC-specific mortality and 0.77 (95% CI: 0.57–1.03; Ptrend = 0.04) for overall mortality, compared with the lowest quintile (≤67.5 µg/L). Similarly, participants with SELENOP concentrations in the highest (≥5.07 mg/L) compared with the lowest quintile (≤3.53 mg/L) had HRs of 0.89 (95% CI: 0.64–1.24; Ptrend = 0.39) for CRC-specific mortality and 0.83 (95% CI: 0.62–1.11; Ptrend = 0.17) for overall mortal-ity. Higher prediagnostic exposure to Se within an optimal concentration (100–150 µg/L) might be associated with improved survival among CRC patients, although our results were not statistically significant and additional studies are needed to confirm this potential association. Our findings may stimulate further research on selenium’s role in survival among CRC patients especially among those residing in geographic regions with suboptimal Se availability.

AB - A higher selenium (Se) status has been shown to be associated with lower risk for colorectal cancer (CRC), but the importance of Se in survival after CRC diagnosis is not well studied. The associations of prediagnostic circulating Se status (as indicated by serum Se and selenoprotein P (SELENOP) measurements) with overall and CRC-specific mortality were estimated using multi-variable Cox proportional hazards regression among 995 CRC cases (515 deaths, 396 from CRC) in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Se and SELENOP serum concentrations were measured on average 46 months before CRC diagnosis. Median follow-up time was 113 months. Participants with Se concentrations in the highest quintile (≥100 µg/L) had a multivariable-adjusted hazard ratio (HR) of 0.73 (95% CI: 0.52–1.02; Ptrend = 0.06) for CRC-specific mortality and 0.77 (95% CI: 0.57–1.03; Ptrend = 0.04) for overall mortality, compared with the lowest quintile (≤67.5 µg/L). Similarly, participants with SELENOP concentrations in the highest (≥5.07 mg/L) compared with the lowest quintile (≤3.53 mg/L) had HRs of 0.89 (95% CI: 0.64–1.24; Ptrend = 0.39) for CRC-specific mortality and 0.83 (95% CI: 0.62–1.11; Ptrend = 0.17) for overall mortal-ity. Higher prediagnostic exposure to Se within an optimal concentration (100–150 µg/L) might be associated with improved survival among CRC patients, although our results were not statistically significant and additional studies are needed to confirm this potential association. Our findings may stimulate further research on selenium’s role in survival among CRC patients especially among those residing in geographic regions with suboptimal Se availability.

KW - Cohort

KW - Colorectal cancer

KW - Selenium

KW - Selenoprotein P

KW - Survival

U2 - 10.3390/biomedicines9111521

DO - 10.3390/biomedicines9111521

M3 - Journal article

C2 - 34829750

AN - SCOPUS:85118387477

SN - 2227-9059

VL - 9

JO - Biomedicines

JF - Biomedicines

IS - 11

M1 - 1521

ER -